Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 3/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.53 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.52 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.51 |
| ▸ | HINT1 | P49773 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25458723 | 1.00 | TGM2 (0.61) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL17210948 | 1.00 | TGM2 (0.61) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL15746464 | 1.00 | TGM2 (0.61) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL19763771 | 1.00 | TGM2 (0.61) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL18295135 | 1.00 | TGM2 (0.61) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL15746448 | 0.98 | TGM2 (0.58) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL18016594 | 0.98 | TGM2 (0.58) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL17210952 | 0.98 | TGM2 (0.58) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL15746451 | 0.97 | TGM2 (0.58) | TGM2FUT5KRASNT5EDCPS | |
| SCHEMBL17210963 | 0.97 | TGM2 (0.58) | TGM2FUT5KRASNT5EDCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9597380-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-18 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140147454-A1 | TERMINALLY MODIFIED RNA | MODERNA THERAPEUTICS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | TGM2 2234/4885FUT5 2056/4885KRAS 1591/4885 |
| US-12023371-B2 | Terminally modified RNA | RNGTT, NSUN3, RNMT | TGM2 3781/4885FUT5 641/4885KRAS 2697/4885 |
| US-20140147454-A1 | TERMINALLY MODIFIED RNA | RNGTT, NSUN3, RNMT | TGM2 3781/4885FUT5 641/4885KRAS 2697/4885 |
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | NSUN3, POLRMT, TRDMT1 | TGM2 2945/4885FUT5 261/4885KRAS 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.